Antibodies for the treatment of bacterial infections: current experience and future prospects

Current Opinion in Biotechnology

Volumn 19, Issue 6, 2008, Pages 613-619

  Bebbington, Christopher ^a   Yarranton, Geoffrey ^a  

^a KaloBios Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOLOGY; MONOCLONAL ANTIBODIES;

ANIMAL DISEASES; ANIMAL MODELS OF DISEASES; ANTIBACTERIAL ACTIVITIES; ANTIBODY THERAPEUTICS; ANTIBODY THERAPIES; BACTERIAL INFECTIONS; CLINICAL TRIALS; FUTURE PROSPECTS; HIGH AFFINITIES; IN-VIVO; POSITIVE DATUMS;

ANTIBODIES;

ABTHRAX; ALTASTAPH; ANTHIM; ANTIBODY; AUROGRAB; KB 001; KBPA 101; MDX 066; MDX 1303; MDX 1388; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PAGIBAXIMAB; RAXIBACUMAB; SHIGAMABS; TEFIBAZUMAB; UNCLASSIFIED DRUG; VALORTIM; VANCOMYCIN; VERONATE;

ANTIBACTERIAL ACTIVITY; ANTIBODY AFFINITY; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS; TARGET CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTERIA; BACTERIAL INFECTIONS; NEUTRALIZATION TESTS;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 57049154860     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2008.10.002     Document Type: Review

References (51)

1. LaRocca T.J., Katona L.I., Thanassi D.G., and Benach J.L. Bactericidal action of a complement-independent antibody against relapsing fever Borrelia resides in its variable region. J Immunol 180 (2008) 6222-6228
2. Conti S., Magliani W., Arseni S., Dieci E., Frazzi R., Salati A., Varaldo P.E., and Polonelli L. In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant gram-positive cocci. Mol Med 6 (2000) 613-619
3. Wentworth Jr. P., Wentworth A.D., Zhu X., Wilson I.A., Janda K.D., Eschenmoser A., and Lerner R.A. Evidence for the production of trioxygen species during antibody-catalyzed chemical modification of antigens. Proc Natl Acad Sci U S A 100 (2003) 1490-1493
4. Babior B.M., Takeuchi C., Ruedi J., Gutierrez A., and Wentworth P. Investigating antibody-catalyzed ozone generation by human neutrophils. Proc Natl Acad Sci U S A 100 (2003) 3031-3034
5. Weisman L.E. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. Arch Pediatr 14 Suppl 1 (2007) S31-S34
6. Thackray H., Lassiter H., and Walsh B. Phase II randomized, double blind, placebo-controlled, safety, pharmacokinetics, pharmacodynamics, and clinical activity study in very low birth weight (VLBW) neonates of BSYX-A110, an anti-staphylococcal monoclonal antibody for the prevention of staphylococcal infection. Pediatr Res 59 (2006) 3724 (Abstract)
7. Domanski P.J., Patel P.R., Bayer A.S., Zhang L., Hall A.E., Syribeys P.J., Gorovits E.L., Bryant D., Vernachio J.H., Hutchins J.T., and Patti J.M. Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun 73 (2005) 5229-5232
8. Weems J.J., Steinberg J.P., Filler S., Baddley J.W., Corey G.R., Sampathkumar P., Winston L., John J.F., Kubin C.J., Talwani R., et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 (2006) 2751-2755
9. Burnie J.P., Matthews R.C., Carter T., Beaulieu E., Donohoe M., Chapman C., Williamson P., and Hodgetts S.J. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 68 (2000) 3200-3209
10. Nilsson E., Larsson A., Olesen H.V., Wejåker P.E., and Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol 43 (2008) 892-899
11. Hemachandra S., Kamboj K., Copfer J., Pier G., Green L.L., and Schreiber J.R. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Infect Immun 69 (2001) 2223-2229
12. Lai Z., Kimmel R., Petersen S., Thomas S., Pier G., Bezabeh B., Luo R., and Schreiber J.R. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 23 (2005) 3264-3271
13. Hatano K., Goldberg J.B., and Pier G.B. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate). Infect Immun 63 (1995) 21-26
14. Rosok M.J., Stebbins M.R., Connelly K., Lostrom M.E., and Siadak A.W. Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa. Infect Immun 58 (1990) 3819-3828
15. Meluleni G.J., Grout M., Evans D.J., and Pier G.B. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 155 (1995) 2029-2038
16. Risley A.L., Loughman A., Cywes-Bentley C., Foster T.J., and Lee J.C. Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets. J Infect Dis 196 (2007) 919-927
17. Atkins K.L., Burman J.D., Chamberlain E.S., Cooper J.E., Poutrel B., Bagby S., Jenkins A.T., Feil E.J., and van den Elsen J.M. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol Immunol 45 (2008) 1600-1611
18. Lambris J.D., Ricklin D., and Geisbrecht B.V. Complement evasion by human pathogens. Nat Rev Microbiol 6 (2008) 132-142. A review of the multiple mechanisms used by bacteria to interfere with complement activation.
19. Jongerius I., Köhl J., Pandey M.K., Ruyken M., van Kessel K.P., van Strijp J.A., and Rooijakkers S.H. Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 204 (2007) 2461-2471
20. Fick Jr. R.B., Naegel G.P., Squier S.U., Wood R.E., Gee J.B., and Reynolds H.Y. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest 74 (1984) 236-248
21. Fick Jr. R.B., Baltimore R.S., Squier S.U., and Reynolds H.Y. IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis 151 (1985) 589-598
22. Engel L.S., Hill J.M., Caballero A.R., Green L.C., and O'Callaghan R.J. Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosa. J Biol Chem 273 (1998) 16792-16797
23. Smith L., Rose B., Tingpej P., Zhu H., Conibear T., Manos J., Bye P., Elkins M., Willcox M., Bell S., et al. Protease IV production in Pseudomonas aeruginosa from the lungs of adults with cystic fibrosis. J Med Microbiol 55 (2006) 1641-1644
24. Britigan B.E., Railsback M.A., and Cox C.D. The Pseudomonas aeruginosa secretory product pyocyanin inactivates alpha1 protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease. Infect Immun 67 (1999) 1207-1212
25. Karlsson A., and Arvidson S. Variation in extracellular protease production among clinical isolates of Staphylococcus aureus due to different levels of expression of the protease repressor sarA. Infect Immun 70 (2002) 4239-4246
26. Rooijakkers S.H., van Wamel W.J., Ruyken M., van Kessel K.P., and van Strijp J.A. Anti-opsonic properties of staphylokinase. Microbes Infect 7 (2005) 476-484
27. Mathee K., Ciofu O., Sternberg C., Lindum P.W., Campbell J.I., Jensen P., Johnsen A.H., Givskov M., Ohman D.E., Molin S., et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145 (1999) 1349-1357
28. Cerca N., Jefferson K.K., Oliveira R., Pier G.B., and Azeredo J. Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a biofilm or in the planktonic state. Infect Immun 74 (2006) 4849-4855
29. Cerca N., Jefferson K.K., Maira-Litrán T., Pier D.B., Kelly-Quintos C., Goldmann D.A., Azeredo J., and Pier G.B. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 75 (2007) 3406-3413
30. Pier G.B., Boyer D., Preston M., Coleman F.T., Llosa N., Mueschenborn-Koglin S., Theilacker C., Goldenberg H., Uchin J., Priebe G.P., et al. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol 173 (2004) 5671-5678
31. March J.C., and Bentley W.E. Quorum sensing and bacterial cross-talk in biotechnology. Curr Opin Biotechnol 15 (2004) 495-502
32. Kravchenko V.V., Kaufmann G.F., Mathison J.C., Scott D.A., Katz A.Z., Grauer D.C., Lehmann M., Meijler M.M., Janda K.D., and Ulevitch R.J. Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule. Science 321 (2008) 259-263
33. Miyairi S., Tateda K., Fuse E.T., Ueda C., Saito H., Takabatake T., Ishii Y., Horikawa M., Ishiguro M., Standiford T.J., and Yamaguchi K. Immunization with 3-oxododecanoyl-l-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection. J Med Microbiol 55 (2006) 1381-1387
34. Kaufmann G.F., Park J., Mee J.M., Ulevitch R.J., and Janda K.D. The quorum quenching antibody RS2-1G9 protects macrophages from the cytotoxic effects of the Pseudomonas aeruginosa quorum sensing signalling molecule N-3-oxo-dodecanoyl-homoserine lactone. Mol Immunol 45 (2008) 2710-2714
35. Park J., Jagasia R., Kaufmann G.F., Mathison J.C., Ruiz D.I., Moss J.A., Meijler M.M., Ulevitch R.J., and Janda K.D. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 14 (2007) 1119-1127
36. Babin M, Ou Y, Roschke V, Yu A, Subramanian M, Choi G: Protection against inhalation anthrax-induced lethality by a human monoclonal antibody to protective antigen in rabbits and cynomolgus monkeys. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy 2003, (Abstract # 3836).
37. Subramanian G.M., Cronin P.W., Poley G., Weinstein A., Stoughton S.M., Zhong J., Ou Y., Zmuda J.F., Osborn B.L., and Freimuth W.W. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 41 (2005) 12-20
38. Mohamed N., Clagett M., Li J., Jones S., Pincus S., D'Alia G., Nardone L., Babin M., Spitalny G., and Casey L. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 73 (2005) 795-802
39. Vitale L., Blanset D., Lowy I., O'Neill T., Goldstein J., Little S.F., Andrews G.P., Dorough G., Taylor R.K., and Keler T. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 74 (2006) 5840-5847
40. Dowling T.C., Chavaillaz P.A., Young D.G., Melton-Celsa A., O'Brien A., Thuning-Roberson C., Edelman R., and Tacket C.O. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 49 (2005) 1808-1812
41. Babcock G.J., Broering T.J., Hernandez H.J., Mandell R.B., Donahue K., Boatright N., Stack A.M., Lowy I., Graziano R., Molrine D., Ambrosino D.M., and Thomas W.D. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74 (2006) 6339-6347
42. Müller S., Feldman M.F., and Cornelis G.R. The Type III secretion system of Gram-negative bacteria: a potential therapeutic target?. Expert Opin Ther Targets 5 (2001) 327-339. This review provides a detailed description of the needle-like type III secretion systems used for the injection of exotoxins by many Gram-negative bacteria.
43. Feltman H., Schulert G., Khan S., Jain M., Peterson L., and Hauser A.R. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147 (2001) 2659-2669
44. Hauser A.R., Cobb E., Bodi M., Mariscal D., Vallés J., Engel J.N., and Rello J. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 30 (2002) 521-528
45. Frank D.W., Vallis A., Wiener-Kronish J.P., Roy-Burman A., Spack E.G., Mullaney B.P., Megdoud M., Marks J.D., Fritz R., and Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 186 (2002) 64-73
46. Faure K., Fujimoto J., Shimabukuro D.W., Ajayi T., Shime N., Moriyama K., Spack E.G., Wiener-Kronish J.P., and Sawa T. Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Ther Vaccines 1 (2003) 2-10
47. Dacheux D., Toussaint B., Richard M., Brochier G., Croize J., and Attree I. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infect Immun 68 (2000) 2916-2924
48. Arnon S.S., Schechter R., Maslanka S.E., Jewell N.P., and Hatheway C.L. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354 (2006) 462-471
49. Cegelski L., Marshall G.R., Eldridge G.R., and Hultgren S.J. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6 (2008) 17-27
50. Edgington S. What went wrong with Centoxin?. Biotechnology 10 (1992) 617. This brief review describes some of the potential pitfalls of antibody development in the field of infectious disease.
51. Ferreira C.S., Li J., Pincus S.E., Casey L.S., Mohamed N., Kreiswirth B.N., and Jones S.M. A heteropolymer against Staphylococcal protein A prevents spread of blood-borne Staphylococcus aureus to target organs. Presented at 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December (2005)